{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"omics_type":["Unknown"],"submitter":["Mohn N"],"pubmed_abstract":["<h4>Importance</h4>Progressive multifocal leukoencephalopathy (PML) is a life-threatening demyelinating disease caused by reactivation of the JC virus (JCV) in immunocompromised patients. While immune checkpoint inhibitors (ICIs) show therapeutic potential, responses vary and predictive biomarkers are lacking.<h4>Objective</h4>To determine whether pretreatment JCV- and/or BK virus-specific T cells in the blood are associated with treatment efficacy.<h4>Design, setting, and participants</h4>This retrospective cohort study included 111 patients with PML who were treated with ICIs stratified by peripheral virus-specific T cell presence (ELISpot/flow cytometry) between August 2021 and May 2024, with a median (IQR) follow-up of 7 (1-13) months. Of 112 patients with definite PML across 39 center"],"journal":["JAMA neurology"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC12820779"],"repository":["biostudies-literature"],"pubmed_title":["Virus-Specific T Cells and Response to Checkpoint Inhibitors in Progressive Multifocal Leukoencephalopathy."],"pmcid":["PMC12820779"],"pubmed_authors":["Wicklein R","Jelcic I","Del Bello A","Jendretzky KF","Cortese I","Ciron J","Huhnchen P","Warnke C","Berger J","Sommet A","Meuth SG","Konen FF","Gourdon F","Kupper C","Delobel P","Pignolet B","Gnanapavan S","Ouallet JC","Leveneur Y","Tumani H","Dinur-Schejter Y","Bernard-Valnet R","Rauer S","Grimbacher B","Grassl N","Antinori A","Bruggemann N","Ducours M","Goreci Y","Roos-Weil D","Ney D","Immunotherapy for PML Study Group","Karacondi K","Suhs KW","Tischer-Zimmermann S","Schneider R","Zent M","Maecker-Kolhoff B","Grote-Levi L","Pourcher V","Bonifacius A","Sassmann ML","Gasnault J","Kamar N","Eiz-Vesper B","Kapadia R","Aouba A","Beudel M","Zahraeifard S","Perpoint T","Wijburg M","Lambert N","Le Marechal M","Treiner E","Brousse X","Clifford D","Shamriz O","Gaudin M","Nitsch L","Cimini E","Martin-Blondel G","Biotti D","Ribaute C","Shifman T","Manda V","Pawlitzki M","Hoglinger GU","Alt L","Kleinschnitz C","Boltz S","Grauer O","Lhomme S","Harel A","Nay S","Wiendl H","Rakotoarison JR","Mohn N","Ayzenberg I","Klebe S","Pinnetti C","Pul R","Cohen-Aubart F","Bonneau B","Helmchen C","Joly M","Boumaza X","Hildner M","Bonneville F","Brouwer M","Weiss N","Engalenc X","De Menibus L","Lifermann F","Skripuletz T","Mrabet H","Grefkes C","Lajaunie R","Lambotte O","Duffau P","Wyplosz B"],"additional_accession":[]},"is_claimable":false,"name":"Virus-Specific T Cells and Response to Checkpoint Inhibitors in Progressive Multifocal Leukoencephalopathy.","description":"<h4>Importance</h4>Progressive multifocal leukoencephalopathy (PML) is a life-threatening demyelinating disease caused by reactivation of the JC virus (JCV) in immunocompromised patients. While immune checkpoint inhibitors (ICIs) show therapeutic potential, responses vary and predictive biomarkers are lacking.<h4>Objective</h4>To determine whether pretreatment JCV- and/or BK virus-specific T cells in the blood are associated with treatment efficacy.<h4>Design, setting, and participants</h4>This retrospective cohort study included 111 patients with PML who were treated with ICIs stratified by peripheral virus-specific T cell presence (ELISpot/flow cytometry) between August 2021 and May 2024, with a median (IQR) follow-up of 7 (1-13) months. Of 112 patients with definite PML across 39 center","dates":{"release":"2026-01-01T00:00:00Z","publication":"2026 Jan","modification":"2026-06-06T19:28:49.197Z","creation":"2026-06-04T03:10:43.772Z"},"accession":"S-EPMC12820779","cross_references":{"pubmed":["41557340"],"doi":["10.1001/jamaneurol.2025.5318"]}}